On this page
- Quick answer
- Why do different NHS pages quote different criteria?
- The wider NICE recommendation
- The first three primary-care phases
- Which health conditions count in the phased rollout?
- BMI thresholds are adjusted for some ethnic backgrounds
- Does meeting the figures guarantee a prescription?
- What this means at Pathfields
- A separate route for type 2 diabetes
- Official sources
Quick answer
In England, Mounjaro (tirzepatide) for weight management is being introduced through the NHS in phases. Primary-care access is initially focused on people with the greatest clinical need, using both BMI and specific weight-related health conditions.
Meeting the wider NICE criteria does not necessarily mean that Mounjaro is available to you through your GP immediately. Local services must also be ready, and a clinician still needs to confirm that treatment is suitable and safe.
Why do different NHS pages quote different criteria?
There are two related sets of criteria:
- The overall NICE recommendation describes the wider group for whom tirzepatide can be a cost-effective NHS treatment.
- The NHS England funding variation phases primary-care access over time because the number of potentially eligible people is much greater than services can safely support all at once.
This is why someone may meet the overall NICE recommendation but not yet be in the current primary-care priority group.
The wider NICE recommendation
NICE recommends tirzepatide as an option for adults with an initial BMI of 35 kg/m² or above and at least one weight-related health condition, when the medicine is considered suitable alongside dietary and physical-activity support.
This is broader than the early NHS England primary-care cohorts described below.
The first three primary-care phases
Each new phase adds another priority group; people in earlier groups remain eligible. The published timetable is approximate and access depends on local implementation.
At least four of the five qualifying health conditions.
At least four of the five qualifying health conditions.
Three of the five qualifying health conditions.
These phases describe access through primary care for weight management. NHS England says the full NICE-eligible population should be reached over a maximum period of 12 years, prioritised according to clinical need.
Which health conditions count in the phased rollout?
- high blood pressure
- dyslipidaemia, meaning abnormal blood fats such as cholesterol or triglycerides
- obstructive sleep apnoea
- cardiovascular disease, such as heart or blood-vessel disease
- type 2 diabetes
A clinician must confirm whether a condition meets the relevant definition. Having another obesity-related condition does not automatically mean that it counts as one of these five for the current primary-care cohort.
BMI thresholds are adjusted for some ethnic backgrounds
The qualifying BMI is usually reduced by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.
For example, a threshold of 40 becomes 37.5, and a threshold of 35 becomes 32.5. This adjustment recognises that health risks can occur at a lower BMI in these groups.
Does meeting the figures guarantee a prescription?
No. The figures identify people who may be eligible for assessment; they do not guarantee that tirzepatide is the right medicine for an individual. The clinical team must also consider your medical history, other medicines, possible contraindications, treatment preferences and whether appropriate ongoing monitoring and behavioural support are available.
Local NHS services may introduce each phase at different times as pathways and capacity are established. Access through a specialist weight-management service may also follow a different local referral route.
What this means at Pathfields
Pathfields will use the current national criteria and the agreed local pathway when identifying people who may be suitable for assessment. Patients in the highest-priority groups will be approached in stages as the service is introduced.
This page will be updated as national guidance and local arrangements develop.
A separate route for type 2 diabetes
Tirzepatide can also be prescribed to some people for the treatment of type 2 diabetes under separate NICE guidance. That is a different prescribing decision from receiving Mounjaro specifically for weight management.
Official sources
NHS England: interim commissioning guidance for tirzepatide
NICE TA1026: tirzepatide for managing overweight and obesity
First published July 2026. Last reviewed: 19 July 2026. Planned review: October 2026, or earlier if NHS England changes the rollout.
Prepared for the Pathfields Healthy Living Portal.